CompletedNCT00227305
Quetiapine for adolescents with schizophrenia or bipolarity
About this title
Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder
Read the official source — NCT00227305Medication studyAges 10–17Multiple countries
Understand this study
Who was this study for?
Listed age limits: 10 years to 17 years.
- Listed locations
- Dothan and 47 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 381
- Sponsor
- AstraZeneca
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, India, Malaysia, ...
- Age range
- From 10 Years to 17 Years
- Official registry ID
- NCT00227305
- Official title
Show the full official title
A 26-week, Multicenter, Open-label Phase 3b Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in Children and Adolescents With Bipolar I Disorder and Adolescents With Schizophrenia (Abbreviated)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Dothan, United States · Scottsdale, United States · Cerritos, United States
46 more locations
- Riverside, United States
- Sacramento, United States
- San Diego, United States
- Denver, United States
- Altamonte Springs, United States
- Jacksonville, United States
- Miami, United States
- Chicago, United States
- Oak Brook, United States
- Newton, United States
- Overland Park, United States
- New Orleans, United States
- Las Vegas, United States
- Rochester, United States
- Cincinnati, United States
- Cleveland, United States
- Lyndhurst, United States
- Oklahoma City, United States
- Philadelphia, United States
- Memphis, United States
- Austin, United States
- Houston, United States
- San Antonio, United States
- Richmond, United States
- Virginia Beach, United States
- Bellevue, United States
- Kirkland, United States
- Milwaukee, United States
- Lucknow, India
- Kuala Lumpur, Malaysia
- Petaling Jaya, Malaysia
- Davao City, Philippines
- Mandaluyong, Philippines
- Manila, Philippines
- Quezon City, Philippines
- Poznan, Poland
- Torun, Poland
- Moscow, Russia
- Saint Petersburg, Russia
- Belgrade, Serbia
- Novi Sad, Serbia
- Pretoria, South Africa
- Kharkiv, Ukraine
- Lviv, Ukraine
- Odesa, Ukraine
- Russia
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is AstraZeneca.
Did this study involve medication?
Yes. The study involved medication, including quetiapine fumarate.
Who was this study for?
Listed age limits: 10 years to 17 years.
